InflaRx N.V.: Commodore Capital LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Commodore Capital LP amended its Schedule 13G filing on InflaRx N.V., updating its beneficial ownership stake in the German biopharmaceutical company. The filing, submitted to the SEC under accession number 0001831942-26-000047, reflects a change to the investor's previously reported position. Schedule 13G amendments are typically filed by passive investors whose holdings cross or adjust around the 5% threshold. The update signals a shift in institutional ownership of InflaRx, a clinical-stage developer of complement-targeted therapies. Investors will watch for further 13G or 13D filings to gauge whether Commodore's position continues to change.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
InflaRx N.V., Commodore Capital LP